Dose-response improvements in glycaemic control and body weight reduction with HM11260C, a once weekly GLP-1 receptor agonist with liraglutide as reference, in type 2 diabetes.[abstract]
Symptoms include fast heartbeat, shaking, sweating, nervousness or anxiety, irritability or confusion and dizziness
A limitation of this analysis is that per registry inclusion criteria, patients could have started or switched to a biologic therapy within 12 months prior to the enrollment date
Sex, body size, reproductive health, gastrointestinal tolerance, and other medicines may affect risk
Willson, Mihir Desai, Peter Middleton Critical review of the manuscript for important intellectual content: Love Patel, Conner M
Common side effects include nausea, vomiting, constipation, and appetite suppression, typically mild and transient